ArticleFrontiers in cardiovascular medicine2025
Circulating biomarkers associated with pyroptosis in the differential diagnosis of ST-segment elevation and non-ST-segment elevation myocardial infarction.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Direct and indirect evidence for pyroptosis and immune dysregulation in IVF/ICSI-ET-related early pregnancy loss.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the biomarker value of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3), gasdermin D (GSDMD), caspase-1, interleukin 1β (IL-1β), and IL-18 in the systemic circulation in ST-elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) as a possible new biomarker candidate, and to compare their sensitivity and specificity to well-defined and built in biomarkers in acute myocardial infarction (AMI), including high sensitive-cardiac troponin I (hs-cTnI) and N-terminal proBNP (NT-proBNP) in patients with STEMI or NSTEMI. Methods: The study included 149 patients with acute STEMI, 151 patients with NSTEMI, and 151 healthy volunteers in the check-up outpatient clinic, admitted to Sisli Hamidiye Etfal Education and Research Hospital, Emergency Department, Istanbul. Results: CK-MB, hs-cTnI, pro-BNP, NLRP3, GSDMD, caspase-1, IL-1β, and IL-18 levels were higher in the STEMI group compared to the other groups, whereas these parameters were lower in the control group compared to the NSTEMI groups. hs-cTnI, CK-MB, caspase-1, IL-1β, and IL-18 showed high sensitivity and specificity, suggesting their potential as reliable diagnostic markers in STEMI patients. Conclusions: NLRP3 inflammasome may play a role in the production of pro-inflammatory cytokines such as IL-1β and IL-18 in STEMI. Inflammasome-related biomarkers show potential as adjunctive tools for distinguishing between STEMI and NSTEMI; however, further studies with multiple timepoints and larger sample sizes are needed to confirm their diagnostic utility and clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.